REL-1015 (LevoCap ER)
Our most-advanced novel version of a proven drug product, REL-1015 (LevoCap ER), is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone, and other strong opioids for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. In particular, levorphanol binds to all three opioid receptor subtypes involved in analgesia (mu, kappa, and delta), the N-methyl-D-aspartate (NMDA) receptor and the norepinephrine and serotonin uptake pumps, whereas morphine is relatively selective for mu sites. The dual mechanism of action of levorphanol, combining opioid receptor agonism with noradrenaline reuptake inhibition in the same molecule makes levorphanol a useful analgesic to treat chronic and neuropathic pain in addition to providing pain relief in patients resistant to other strong opioids. Levorphanol is a strong opioid first developed in the 1940s as an alternative to morphine and has greater potency than morphine. In clinical studies, it has demonstrated a remarkably broad spectrum of analgesic activity against many different types of pain including neuropathic pain, post-surgical pain, and chronic pain in patients refractory to other opioids.
LevoCap ER Pipeline
|Preclinical||Phase 1||Phase 2||Phase 3|
Projected stage of development in 12-24 months
- Clinically and pharmacologically differentiated from other strong opioids
- Effective in nociceptive and neuropathic pain
- Once or twice a day extended release formulation
- Abuse deterrent and tamper resistant
The chronic pain market is a very large market with growth expected in certain segments including cancer pain, low back pain and osteoarthritis in line with the aging population. In the US alone, there were 334 milion prescriptions written for pain in 2014. In financial terms the market is valued at $21 billion globally with approximately $14 billion in the US.
The opioid segment of the chronic pain market in major markets is valued at $8 billion. Chronic low back pain is the leading diagnosis for use of strong opioids (approx. 50%), followed by chronic cancer pain (approx. 25%). Relmada expects that REL-1015 will be positioned for patients who require an opioid for moderate to severe chronic pain with a neuropathic component or mixed neuropathic/nociceptive pain (cancer patients, low back pain).
By the Numbers
Patients currently being prescribed opioids in combination with other pain relievers
Prescriptions written for pain in the U.S. in 2014
U.S. individuals who say their pain is under control
Potential Large Target Populations
- Cancer pain
- Chronic non-cancer pain
- Low back pain
- Idiopathic pain
- Neuropathic pain
How it Works
REL-1015’s multi-modal mechanism of action provides for a more robust efficacy profile and could potentially be used alone for patients who take multiple drugs.
Works to inhibit pain by binding to opioid receptors.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) affect the nerve cells in the brain and inhibit the reuse of specific neurotransmitters to enhance inhibition of pain signaling.
Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL™, its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
The new SECUREL patent application is entitled "Multimodal Abuse Resistant and Extended Release Opioid Formulations." Once granted, the patent is expected to be valid until at least 2028.